NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach

Reuters

2025/05/20

NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach

CARMEL, Ind., May 20, 2025 - NeurAxis, Inc., a medical technology company, has announced it has received FDA 510(k) clearance for its IB-Stim™ device to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and related nausea symptoms in patients aged 8 to 21 years. This marks a significant achievement as it is the first treatment ever cleared by the FDA for functional dyspepsia, expanding IB-Stim's total addressable market significantly. The clearance, which follows the device's initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS), further solidifies NeurAxis' leadership in non-invasive, pediatric-focused neuromodulation. The company's President and CEO, Brian Carrico, highlighted the strategic importance of this milestone, emphasizing the potential for substantial revenue growth and increased insurance coverage. The American Medical Association's recent approval of a new CPT Category I code for IB-Stim, effective January 2026, is expected to support this expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9454793-en) on May 20, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536820612"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536820612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536820612?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536820612","market":"nz","top_or_hot":-1,"title":"NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARMEL, Ind., May 20, 2025 - NeurAxis, Inc., a medical technology company, has announced it has received FDA 510(k) clearance for its IB-Stim™ device to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and related nausea symptoms in patients aged 8 to 21 years. This marks a significant achievement as it is the first treatment ever cleared by the FDA for functional dyspepsia, expanding IB-Stim's total addressable market significantly. The clearance, which follows the device's initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS), further solidifies NeurAxis' leadership in non-invasive, pediatric-focused neuromodulation. The company's President and CEO, Brian Carrico, highlighted the strategic importance of this milestone, emphasizing the potential for substantial revenue growth and increased insurance coverage. The American Medical Association's recent approval of a new CPT Category I code for IB-Stim, effective January 2026, is expected to support this expansion.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9454793-en) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARMEL, Ind., May 20, 2025 - NeurAxis, Inc., a medical technology company, has announced it has received FDA 510(k) clearance for its IB-Stim™ device to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and related nausea symptoms in patients aged 8 to 21 years. This marks a significant achievement as it is the first treatment ever cleared by the FDA for functional dyspepsia, expanding IB-Stim's total addressable market significantly. The clearance, which follows the device's initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS), further solidifies NeurAxis' leadership in non-invasive, pediatric-focused neuromodulation. The company's President and CEO, Brian Carrico, highlighted the strategic importance of this milestone, emphasizing the potential for substantial revenue growth and increased insurance coverage. The American Medical Association's recent approval of a new CPT Category I code for IB-Stim, effective January 2026, is expected to support this expansion.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9454793-en) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL5ldbJ1:1","article_id":"2536820612","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536820612","pubTimestamp":1747742418,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire  on May 20, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","NRXS":"Neuraxis, Inc."},"translate_title":"NeurAxis Inc.获得FDA批准IB-Stim治疗儿科功能性消化不良和相关恶心，扩大市场范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NRXS":0.9},"content_text":"NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach\n    \n\n        CARMEL, Ind., May 20, 2025 - NeurAxis, Inc., a medical technology company, has announced it has received FDA 510(k) clearance for its IB-Stim™ device to treat Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and related nausea symptoms in patients aged 8 to 21 years. This marks a significant achievement as it is the first treatment ever cleared by the FDA for functional dyspepsia, expanding IB-Stim's total addressable market significantly. The clearance, which follows the device's initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS), further solidifies NeurAxis' leadership in non-invasive, pediatric-focused neuromodulation. The company's President and CEO, Brian Carrico, highlighted the strategic importance of this milestone, emphasizing the potential for substantial revenue growth and increased insurance coverage. The American Medical Association's recent approval of a new CPT Category I code for IB-Stim, effective January 2026, is expected to support this expansion.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9454793-en) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}